Reviewing Spring Bank Pharmaceuticals Inc. (SBPH)’s and Arbutus Biopharma Corporation (NASDAQ:ABUS)’s results

Both Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) and Arbutus Biopharma Corporation (NASDAQ:ABUS) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spring Bank Pharmaceuticals Inc. N/A 0.00 18.89M -1.37 0.00
Arbutus Biopharma Corporation 6.80M 31.74 83.10M -1.81 0.00

Table 1 demonstrates Spring Bank Pharmaceuticals Inc. and Arbutus Biopharma Corporation’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) and Arbutus Biopharma Corporation (NASDAQ:ABUS)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Spring Bank Pharmaceuticals Inc. 0.00% -47.4% -34.4%
Arbutus Biopharma Corporation -1,222.06% -72.9% -32.3%

Liquidity

Spring Bank Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 10.7 and 10.7 respectively. The Current Ratio and Quick Ratio of its competitor Arbutus Biopharma Corporation are 11.4 and 11.4 respectively. Arbutus Biopharma Corporation therefore has a better chance of paying off short and long-term obligations compared to Spring Bank Pharmaceuticals Inc.

Insider & Institutional Ownership

Roughly 42.9% of Spring Bank Pharmaceuticals Inc. shares are owned by institutional investors while 43.5% of Arbutus Biopharma Corporation are owned by institutional investors. About 4% of Spring Bank Pharmaceuticals Inc.’s share are owned by insiders. On the other hand, insiders owned about 3.3% of Arbutus Biopharma Corporation’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Spring Bank Pharmaceuticals Inc. -9.25% -13.63% -19.94% -26.09% -19.62% -24.11%
Arbutus Biopharma Corporation 2.06% -10.1% -55.5% -25.21% -12.75% -11.88%

For the past year Spring Bank Pharmaceuticals Inc. was more bearish than Arbutus Biopharma Corporation.

Summary

On 5 of the 9 factors Arbutus Biopharma Corporation beats Spring Bank Pharmaceuticals Inc.

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its SMNH compounds are small segments of nucleic acids that the company designs to target and modulate the activity of specific proteins implicated in various disease states. The companyÂ’s lead product candidate is SB 9200, which completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus and respiratory syncytial virus. It also develops SMNH product candidate, SB 11285, an immunotherapeutic agent for the treatment of selected cancers; and SB 9400, SB 9941, and SB 9946 preclinical product candidates for viral diseases. The company has an agreement with Arrowhead Pharmaceuticals, Inc. to collaborate on the study of the combined use of SB 9200 and small interfering ribonucleic acid product pipeline for the treatment of chronic hepatitis B virus (HBV); and Arbutus Biopharma Corporation to collaborate on the preclinical study of the combined use of SB 9200 and AB-423, a capsid assembly inhibitor for the treatment of chronic HBV. It also has a clinical trial collaboration agreement with Gilead Sciences, Inc. for a clinical study examining the use of SB 9200 co-administered with GileadÂ’s Vemlidy (tenofovir alafenamide) in chronic HBV patients. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also comprise ARB-1740, a pan-genotypic second-generation siRNA therapeutic in Phase II multi-dose study in Hepatitis B e antigen-chronic HBV patients; and AB-423, a core protein/capsid assembly inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates, including oral surface antigen inhibitors, cccDNA targeting agents, and immunomodulators. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) in Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and DCR-PH1 for the treatment of primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.